Efter seks måneder var andelen af patienter, der responderede på behandlingen, 95% i den ene undersøgelse og 97% i den anden undersøgelse, sammenlignet med 75% og 73% af de patienter, der fik risedronat.
After six months, the proportion of patients who had responded to treatment was 95% in one study and 97% in the other, compared with 75% and 73% of the patients who received risedronate.